Cartesian Therapeutics annual shares outstanding
2015
2016
2019
2020
2021
2022
2023
2024
2025
Cartesian Therapeutics Shares Outstanding History (RNAC)
Cartesian Therapeutics reported 26.0M shares outstanding at the end of fiscal 2025.
View full Cartesian Therapeutics company overviewCartesian Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 26.0M | 243,737 | +0.95% |
| 2024 | 2024-12-31 | 25.8M | 20.4M | +377.39% |
| 2023 | 2023-12-31 | 5.4M | 301,283.914 | +5.91% |
| 2022 | 2022-12-31 | 5.1M | 979,668.351 | +23.80% |
| 2021 | 2021-12-31 | 4.1M | 517,872.143 | +14.39% |
| 2020 | 2020-12-31 | 3.6M | 724,131.877 | +25.19% |
| 2019 | 2019-12-31 | 2.9M | 2.3M | +368.17% |
| 2016 | 2016-12-31 | 614,010.109 | 541,635.922 | +748.38% |
| 2015 | 2015-12-31 | 72,374.187 | — | — |
Cartesian Therapeutics quarterly shares outstanding
Q4.15
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
As of Dec 31, 2017
As of Mar 31, 2018
As of Jun 30, 2018
As of Sep 30, 2018
As of Dec 31, 2018
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 30.0M | 4.0M | +15.53% |
| Q1 2026 | 2026-03-31 | 28.5M | 2.6M | +10.06% |
| Q4 2025 | 2025-12-31 | 26.0M | 243,737 | +0.95% |
| Q3 2025 | 2025-09-30 | 26.0M | 2.1M | +8.82% |
| Q2 2025 | 2025-06-30 | 26.0M | 8.2M | +45.93% |
| Q1 2025 | 2025-03-31 | 25.9M | 25.8M | +14020.47% |
| Q4 2024 | 2024-12-31 | 25.8M | 25.6M | +14235.91% |
| Q3 2024 | 2024-09-30 | 23.9M | 18.7M | +363.41% |
| Q2 2024 | 2024-06-30 | 17.8M | 12.7M | +248.71% |
| Q1 2024 | 2024-03-31 | 183,677.339 | −4.9M | −96.40% |
| Q4 2023 | 2023-12-31 | 179,739.98 | −4.9M | −96.47% |
| Q3 2023 | 2023-09-30 | 5.2M | 60,779.493 | +1.19% |
| Q2 2023 | 2023-06-30 | 5.1M | 23,788.188 | +0.47% |
| Q1 2023 | 2023-03-31 | 5.1M | 967,236.429 | +23.35% |
| Q4 2022 | 2022-12-31 | 5.1M | 979,668.351 | +23.80% |
| Q3 2022 | 2022-09-30 | 5.1M | 1.3M | +32.56% |
| Q2 2022 | 2022-06-30 | 5.1M | 1.3M | +32.70% |
| Q1 2022 | 2022-03-31 | 4.1M | 379,747.872 | +10.09% |
| Q4 2021 | 2021-12-31 | 4.1M | 517,872.143 | +14.39% |
| Q3 2021 | 2021-09-30 | 3.8M | 273,310.549 | +7.65% |
| Q2 2021 | 2021-06-30 | 3.8M | 473,908.351 | +14.11% |
| Q1 2021 | 2021-03-31 | 3.8M | 864,395.806 | +29.83% |
| Q4 2020 | 2020-12-31 | 3.6M | 724,131.877 | +25.19% |
| Q3 2020 | 2020-09-30 | 3.6M | 2.0M | +122.50% |
| Q2 2020 | 2020-06-30 | 3.4M | 1.9M | +124.34% |
| Q1 2020 | 2020-03-31 | 2.9M | 1.4M | +94.29% |
| Q4 2019 | 2019-12-31 | 2.9M | 2.1M | +284.15% |
| Q3 2019 | 2019-09-30 | 1.6M | 859,146.793 | +115.20% |
| Q2 2019 | 2019-06-30 | 1.5M | 751,140.374 | +100.72% |
| Q1 2019 | 2019-03-31 | 1.5M | 747,191.561 | +100.40% |
| As of Dec 31, 2018 | 2018-12-31 | 748,310.141 | 4,279.783 | +0.58% |
| As of Sep 30, 2018 | 2018-09-30 | 745,792.894 | 9,180.011 | +1.25% |
| As of Jun 30, 2018 | 2018-06-30 | 745,792.894 | 11,323.199 | +1.54% |
| As of Mar 31, 2018 | 2018-03-31 | 744,249.672 | 126,455.252 | +20.47% |
| As of Dec 31, 2017 | 2017-12-31 | 744,030.358 | 130,020.25 | +21.18% |
| Q3 2017 | 2017-09-30 | 736,612.883 | 130,942.06 | +21.62% |
| Q2 2017 | 2017-06-30 | 734,469.695 | 138,538.756 | +23.25% |
| Q1 2017 | 2017-03-31 | 617,794.421 | 545,420.234 | +753.61% |
| Q4 2016 | 2016-12-31 | 614,010.109 | — | — |
| Q3 2016 | 2016-09-30 | 605,670.823 | — | — |
| Q2 2016 | 2016-06-30 | 595,930.939 | — | — |
| Q4 2015 | 2015-12-31 | 72,374.187 | — | — |
Cartesian Therapeutics shares outstanding trends
Over the last five reported fiscal years, Cartesian Therapeutics's shares outstanding moved from 3.6M to 26.0M, a change of 22.4M. The latest reported quarter, Q2 2026, shows 30.0M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cartesian Therapeutics filings at SEC.gov ↗